Drug Trial Radar · NCT02105701
Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)
Last checked: Nov 19, 2026Latest source record: Feb 5, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
420
Actual
Start
Jun 5, 2014
Primary completion
Mar 24, 2015
Study completion Jun 19, 2015
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Apr 7, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an efficacy and safety study of grazoprevir (MK-5172) in combination with elbasvir (MK-8742) with or without ribavirin (RBV) in participants with chronic hepatitis C virus (HCV) genotype (GT) 1, 4, or 6 infections who have failed prior therapy with pegylated interferon and RBV. The primary study hypothesis is that in at least one of the study arms, the percentage of participants achieving sustained viral response 12 weeks after the end of all study treatment (SVR12) will be superior to 58%.
Conditions
- Hepatitis C Infection
Interventions
Grazoprevir + ElbasvirDrug
FDC tablet containing grazoprevir 100 mg and elbasvir 50 mg.
RibavirinDrug
200 mg capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving Undetectable HCV RNA 12 Weeks After Completing Study Therapy (SVR12)Time frame: 12 weeks after the end of all study treatment (up to 28 weeks)
- Number of Participants Experiencing Adverse Events (AE)Time frame: Up to 18 weeks
- Number of Participants Discontinuing Study Treatment Due to an AETime frame: Up to 16 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.